Patent number: 10851346
Abstract: The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-? and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII.
Type:
Grant
Filed:
August 14, 2014
Date of Patent:
December 1, 2020
Assignee:
THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY—ACADEMIC COOPERATION FOUNDATION
Inventors:
Chul Woo Yang, Mi-La Cho, Sung-Hwan Park, Eun Kyung Kim, Byung Ha Chung, Kyoung-Woon Kim, Seon-Yeong Lee, Sung-Hee Lee, Eun Ji Yang, Jeong-hee Jeong, Min Jung Park, Seok-Jung Kim, Eun-Jung Lee, Su-Jin Moon